A detailed history of Bank Julius Baer & Co. Ltd, Zurich transactions in Veracyte, Inc. stock. As of the latest transaction made, Bank Julius Baer & Co. Ltd, Zurich holds 19,463 shares of VCYT stock, worth $795,842. This represents 0.0% of its overall portfolio holdings.

Number of Shares
19,463
Holding current value
$795,842
% of portfolio
0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$21.0 - $35.25 $408,723 - $686,070
19,463 New
19,463 $662,000
Q1 2024

May 14, 2024

SELL
$21.0 - $29.1 $67,389 - $93,381
-3,209 Reduced 8.88%
32,947 $730,000
Q4 2023

May 16, 2024

BUY
$19.72 - $28.68 $63,281 - $92,034
3,209 Added 9.74%
36,156 $994,000
Q4 2023

Feb 02, 2024

SELL
$19.72 - $28.68 $6,054 - $8,804
-307 Reduced 0.84%
36,156 $995,000
Q3 2023

Nov 13, 2023

BUY
$22.33 - $29.92 $26,885 - $36,023
1,204 Added 3.41%
36,463 $814,000
Q2 2023

Jul 24, 2023

BUY
$20.96 - $26.99 $739,028 - $951,640
35,259 New
35,259 $898,000
Q1 2023

May 11, 2023

BUY
$20.58 - $27.89 $57,006 - $77,255
2,770 Added 7.89%
37,881 $845,000
Q4 2022

Jan 24, 2023

BUY
$15.31 - $29.94 $44,429 - $86,885
2,902 Added 9.01%
35,111 $833,000
Q3 2022

Nov 04, 2022

SELL
$16.58 - $27.9 $320,574 - $539,446
-19,335 Reduced 37.51%
32,209 $535,000
Q2 2022

Jul 22, 2022

SELL
$15.45 - $29.52 $93,410 - $178,477
-6,046 Reduced 10.5%
51,544 $1.03 Million
Q1 2022

May 09, 2022

SELL
$21.94 - $42.51 $1.16 Million - $2.26 Million
-53,090 Reduced 47.97%
57,590 $1.59 Million
Q4 2021

Feb 15, 2022

SELL
$36.09 - $53.79 $11.2 Million - $16.7 Million
-310,009 Reduced 73.69%
110,680 $4.56 Million
Q3 2021

Nov 12, 2021

BUY
$35.62 - $52.97 $15 Million - $22.3 Million
420,689 New
420,689 $19.5 Million

Others Institutions Holding VCYT

About VERACYTE, INC.


  • Ticker VCYT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 71,575,904
  • Market Cap $2.93B
  • Description
  • Veracyte, Inc. operates as a diagnostics company worldwide. The company offers Afirma Genomic Sequencing Classifier and Xpression Atlas, which are used to determine patients with indeterminate results are benign to avoid unnecessary surgery; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer ...
More about VCYT
Track This Portfolio

Track Bank Julius Baer & Co. Ltd, Zurich Portfolio

Follow Bank Julius Baer & Co. Ltd, Zurich and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Julius Baer & Co. Ltd, Zurich, based on Form 13F filings with the SEC.

News

Stay updated on Bank Julius Baer & Co. Ltd, Zurich with notifications on news.